ENGLEWOOD, Colo., Feb. 10, 2022 /PRNewswire/ -- Ampio
Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company
focused on the advancement of immunomodulatory
therapies for prevalent inflammatory conditions, today
announced the appointment of Elizabeth Varki Jobes, Esq. to
the Company's Board of Directors. The appointment of Ms. Jobes
expands the Company's Board of Directors from seven members to
eight.
"We welcome Elizabeth as an addition to our Board of Directors
as we enter into a pivotal period at Ampio," said Mike Martino, Chairman and CEO of Ampio.
"Throughout her impressive career, Elizabeth has amassed extensive
governance and compliance expertise that strengthens our competence
and deepens our skillset as we initiate a discussion with the FDA
on a BLA submission for Ampion in parallel with the pursuit of
a partnership."
Ms. Jobes has nearly three decades of legal and compliance
experience. As a practicing attorney, she has built and guided
compliance and legal programs for small- and medium-size
biopharmaceutical corporations. She currently serves as the Senior
Vice President and Global Chief Compliance Officer at Amryt
Pharmaceuticals Inc., where she led the development and
implementation of a global compliance program following the
acquisition of Aegerion Pharmaceuticals.
Previously, Ms. Jobes held leadership positions at many
biopharmaceutical companies, including: Senior Vice President,
Chief Compliance Officer North America for EMD Serono, Inc.; Global
Chief Compliance Officer and Legal Counsel for Spark Therapeutics,
Inc.; Senior Vice President, Chief Compliance Officer for Auxilium
Pharmaceuticals, Inc.; Vice President, Chief Compliance Officer for
Adolor Corporation; and Senior Director, Global Compliance for
Cephalon, Inc.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company
primarily focused on the advancement of immunology-based therapies
to treat prevalent inflammatory conditions for which there are
limited treatment options. Ampio's lead drug, Ampion™, is backed by
an extensive patent portfolio with intellectual property protection
extending through 2037 and may be eligible for 12-year FDA market
exclusivity upon approval as a novel biologic under the Biologics
Price Competition and Innovation Act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion and its classification, as
well as those associated with regulatory approvals and other FDA
decisions, the Biological License Application (BLA), the ability of
Ampio to enter into partnering arrangements,
clinical trials and decisions and changes in business
conditions and similar events, the ability to receive regulatory
approval to conduct clinical trials, that Ampion may be used to
treat ARDS induced by COVID-19, all of which are inherently subject
to various risks and uncertainties. The risks and uncertainties
involved include those detailed from time to time in Ampio's
filings with the Securities and Exchange Commission, including
without limitation, under Ampio's Annual Report on Form 10-K and
other documents filed with the Securities and Exchange Commission.
Ampio undertakes no obligation to revise or update these
forward-looking statements, whether as a result of new information,
future events or otherwise.
Investor and Media Contacts:
Tony Russo or Nic Johnson
Russo Partners
info@ampiopharma.com
tony.russo@russopartnersllc.com
nic.johnson@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ampio-expands-board-of-directors-with-addition-of-elizabeth-varki-jobes-301479595.html
SOURCE Ampio Pharmaceuticals, Inc.